What has been studied, in what species, at what doses

The short version

There is no validated human dose for the KLOW blend. This page describes what doses were used in the studies that do exist — for the individual components, in the species and contexts where they were studied — so readers can see the basis (or absence of basis) for figures circulating in research-peptide communities.

BPC-157 was studied in rats at roughly 10 micrograms per kilogram for tissue repair, with one 2025 human pilot tolerating 10–20 mg intravenously in two adults. GHK-Cu was used as a 2% topical gel in the most-cited human trial. Full-length thymosin beta-4 (not the TB-500 fragment) was tested intravenously up to 1260 mg in 40 healthy volunteers. KPV was studied in mice at around 205 micrograms per day in drinking water. None of these numbers add up to a KLOW dose — they are what single-agent investigators used in different animals, by different routes, for different questions. No dose-finding study for the four-peptide combination has ever been published.

Why this page reads the way it does

The KLOW blend has never been administered to humans in a controlled clinical trial. There is no published dose-finding study, no pharmacokinetic study, and no defined human dose for the four peptides taken together ^[19].

What exists in the literature is a set of dose ranges that were administered to research animals or, in narrow cases, to small numbers of human volunteers receiving a single component. Those numbers are reported below as research context — what was given to what species under what conditions — not as guidance for any human application. The framing throughout this page is 'studied at X in [species] for [purpose],' never 'an effective dose is X.'

Vendor-supplied 'protocols' that circulate around research peptide blends are not derived from clinical trials and have not been reviewed by any regulatory agency.

BPC-157 research doses

Rodent ligament and tendon healing. BPC-157 at 10 μg/kg or 10 ng/kg intraperitoneally daily improved transected medial collateral ligament biomechanics in rats versus saline controls ^[3]. The same micrograms-per-kilogram range appears in rat Achilles tendon work, with in-vitro tendon fibroblast assays adding 1 μg/mL exposure ^[4].

Rodent intestinal anastomosis. A 2024 review of 30 rodent anastomosis studies catalogs dose ranges from 10 ng/kg to 10 μg/kg administered intraperitoneally, orally, or locally, with consistent improvement in healing across small bowel, large bowel, and esophagus ^[21].

Preclinical toxicology. GLP-style toxicology in rats, dogs, rabbits, and guinea pigs identified no minimum toxic dose and no lethal dose across single and repeat-dose intramuscular and intravenous administration ^[1].

Human pilot data. A 2025 pilot study reported that two healthy adults tolerated single intravenous BPC-157 doses up to 20 mg without adverse events ^[18]. With n=2, this is not a basis for human dose inference.

Plasma half-life. BPC-157 has been estimated at approximately 4 hours in rat plasma. Human pharmacokinetic data is essentially absent.

GHK-Cu research doses

Topical human studies. A 2% GHK-Cu gel was used in the diabetic foot ulcer trial showing improved closure and reduced infection rates ^[6]. Other topical skin and wound studies report similar concentration ranges, typically applied once or twice daily.

In-vitro and oral rodent. The Connectivity Map gene expression work used 1 μM in cultured cells ^[8]. The 2025 colitis study used oral dosing in mice across a small dose range that reduced disease activity and improved goblet cell preservation via SIRT1/STAT3 modulation ^[9].

Research literature reference ranges. Subcutaneous research-context doses commonly cited in the secondary literature are in the 1–3 mg/day range. These are reference ranges from research-peptide literature, not validated human therapeutic doses.

Plasma half-life. GHK-Cu plasma half-life is short — on the order of minutes — due to peptidase activity. The tripeptide is degraded rapidly in circulation, which is part of why most clinical experience is topical.

TB-500 and full-length Tβ4 research doses

Full-length Thymosin Beta-4 — Phase 1 intravenous. Single intravenous doses of 42, 140, 420, or 1260 mg were administered to healthy volunteers, with daily dosing for 14 days at the higher levels, in the Phase 1 trial of 40 subjects. No dose-limiting toxicities were observed at any tested dose ^[10].

Full-length Tβ4 — Phase 2 ophthalmic. A 0.1% topical solution was administered six times daily for 28 days in the severe dry eye trial ^[11].

TB-500 fragment. No validated human dose has been published for the synthetic 7-amino-acid LKKTETQ fragment as distinct from full-length Tβ4. Doses circulated in unpublished and secondary literature commonly reference 2–5 mg twice weekly, but these are vendor or community figures, not published clinical findings.

Half-life. Full-length Tβ4 plasma half-life has been reported at approximately 2 hours in rats. The TB-500 fragment's pharmacokinetics are poorly characterized.

KPV research doses

Mouse colitis — oral. 205 μg/day delivered in drinking water reduced DSS- and TNBS-induced colitis severity, with nanomolar concentrations sufficient for NF-κB and MAP kinase inhibition in cellular assays ^[13].

Mouse colitis — nanoparticle-encapsulated oral. HA-KPV-NPs (~272 nm hyaluronic-acid-functionalized nanoparticles) delivered KPV orally to colonic epithelial cells and macrophages, accelerating mucosal healing in a DSS murine model ^[14].

Research literature reference ranges. Secondary literature commonly cites 250–500 μg/day oral as the research-context range for rodent colitis work. No human dose has been validated.

Half-life and uptake. Plasma half-life is on the order of 1–2 hours; tissue retention is longer because of PepT1-mediated cellular uptake. KPV is degraded by aminopeptidases in solution.

Blend reconstitution and the absence of a combined dose

KLOW vials are sold lyophilized at varying total masses, most commonly 80 mg per vial with a 50:10:10:10 mg ratio across GHK-Cu, BPC-157, TB-500, and KPV. Some vendors offer 70 mg total or alternative ratios such as 50:10:15:15. There is no industry-wide standard.

Reconstitution is typically performed with bacteriostatic water (sterile water containing 0.9% benzyl alcohol, which inhibits bacterial growth in multi-dose vials). Vendor reconstitution guidance varies; reconstituted product is generally reported stable for 2–4 weeks at 2–8°C, though stability under real-world freeze-thaw cycling is not validated for the specific blend.

No combined dose-finding study has ever been published for the KLOW blend in any species ^[19]. There is no characterization of how the four peptides distribute, interact, or clear when administered together. Vendor dosing suggestions are not derived from clinical trials.

• *